Crossmark

Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice

Crossref DOI link: https://doi.org/10.1016/j.htct.2022.04.002

Published Print: 2022-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Boquimpani, Carla http://orcid.org/0000-0001-7396-2495
Seguro, Fernanda Salles http://orcid.org/0000-0001-6637-3588
Magalhães, Gustavo Henrique Romani http://orcid.org/0000-0001-5393-8041
Pinto, Ingrid Luise Soares http://orcid.org/0000-0002-1891-464X
Bendit, Israel http://orcid.org/0000-0002-4751-1428
Bortolini, Jaisson André Pagnoncelli http://orcid.org/0000-0001-7298-8570
Pagnano, Katia Borgia Barbosa http://orcid.org/0000-0001-7975-0805
Centrone, Renato http://orcid.org/0000-0002-7145-2552
Funke, Vaneuza http://orcid.org/0000-0002-2122-7277
Funding

Funding for this research was provided by:

Novartis
License Information

Text and Data Mining valid from 2022-07-01

Version of Record valid from 2022-04-22
More Information

This article is maintained by: Elsevier

Article Title: Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice

Journal Title: Hematology, Transfusion and Cell Therapy

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.htct.2022.04.002

Content Type: article

Copyright: © 2022 Published by Elsevier España, S.L.U. on behalf of Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular.

Document is current

Any future updates will be listed below